Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO-AD: Open-label phase IIa pilot study of recombinant human erythropoietin in early mild Alzheimer's dementia and therapy-refractory major depression
2008-000453-35Phase 2Active
- Sponsor
- Max Planck Institute for Multidisciplinary Sciences
- Start
- Feb 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epoetin alfa in Alzheimer's disease (AD) and major depressive disorder (MDD) (2 cohorts), sponsored by Max Planck Institute for Multidisciplinary Sciences. Primary endpoints: Safety and Improvement of affective symptoms (mood). Started Feb 2008; status: active.
02
Drugs
epoetin alfa
03
Conditions
Alzheimer's disease (AD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-000453-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000453-35.